|
| Status |
Public on Jan 09, 2017 |
| Title |
VPM_01_week26 |
| Sample type |
RNA |
| |
|
| Source name |
Whole blood
|
| Organism |
Homo sapiens |
| Characteristics |
group: VPM1002
donor_id: VPM_001
timepoint (weeks post vaccination): 26
|
| Treatment protocol |
Infants were vaccinated with standard dose of BCG or VPM1002
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted from whole blood stored in RNAlater solution (Sigma) using the RiboPure -Blood kit (Ambion)
|
| Label |
Cy3
|
| Label protocol |
RNA was labeled with the Fluorescent Linear Amplification Kit (Agilent Technologies) following manufacturer’s instructions.
|
| |
|
| Hybridization protocol |
Quantity and labelling efficiency were verified before hybridization to human whole genome microarrays (Agilent Technologies)
|
| Scan protocol |
Scanned on an Agilent Scanner G2505B. Image analysis was performed with Feature Extraction software (version 6.1.1, Agilent Technologies).
|
| Description |
Gene expression in whole blood 26 weeks after vaccination
|
| Data processing |
Data were processed, quantile normalized and analyzed using the R package Lima (Ritchie et al (2015). Nucleic Acids Research, 43(7), pp. e47)
|
| |
|
| Submission date |
Sep 09, 2016 |
| Last update date |
Jan 10, 2017 |
| Contact name |
Jeroen Maertzdorf |
| Organization name |
MPIIB
|
| Street address |
Chariteplatz 1
|
| City |
Berlin |
| ZIP/Postal code |
10117 |
| Country |
Germany |
| |
|
| Platform ID |
GPL21272 |
| Series (1) |
| GSE86627 |
Safety and immunogenicity of the recombinant BCG vaccine VPM1002, in South African infants |
|
